(Q28245414)

Crossref

https://api.crossref.org/works/10.1007%2FS11523-009-0114-0

Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab

21 January 2018

1 reference

12 December 2020

Dermatologic side effects associated with the epidermal growth factor receptor inhibitors

1 reference

12 December 2020

Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor

1 reference

12 December 2020

Erlotinib induced skin rash spares skin in previous radiotherapy field.

1 reference

12 December 2020

Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer

1 reference

12 December 2020

Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.

1 reference

12 December 2020

Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models

1 reference

12 December 2020

Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity

1 reference

12 December 2020

Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225

1 reference

12 December 2020

Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management

1 reference

12 December 2020

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

1 reference

12 December 2020

A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter.

1 reference

12 December 2020

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer

1 reference

12 December 2020

Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression

1 reference

12 December 2020

Erlotinib-induced florid acneiform rash complicated by extensive impetiginization

1 reference

12 December 2020

Rash from EGFR inhibitors: opportunities and challenges for palliation

1 reference

12 December 2020

Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment

1 reference

12 December 2020

The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies

1 reference

12 December 2020

The EGF receptor - an essential regulator of multiple epidermal functions

1 reference

12 December 2020

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

1 reference

12 December 2020

Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

12 December 2020

Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies

1 reference

12 December 2020

Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy

1 reference

12 December 2020

Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib

1 reference

12 December 2020

Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab

1 reference

12 December 2020

Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.

1 reference

12 December 2020

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

12 December 2020

Mechanisms of cutaneous toxicities to EGFR inhibitors.

1 reference

12 December 2020

Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway

1 reference

12 December 2020

Cutaneous side-effects of kinase inhibitors and blocking antibodies

1 reference

12 December 2020

Severe cutaneous reaction during radiation therapy with concurrent cetuximab

1 reference

12 December 2020

More on severe cutaneous reaction with radiotherapy and cetuximab

1 reference

12 December 2020

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

12 December 2020

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

1 reference

12 December 2020

Molecular determinants of cetuximab efficacy

1 reference

12 December 2020

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

1 reference

12 December 2020

ERK1/2 regulates epidermal chemokine expression and skin inflammation

1 reference

12 December 2020

Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption

1 reference

12 December 2020

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.

1 reference

12 December 2020

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

12 December 2020

Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies

1 reference

12 December 2020

Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure

1 reference

12 December 2020

Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib

1 reference

12 December 2020

EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation

1 reference

12 December 2020

Pharmacogenomic importance of ABCG2.

1 reference

12 December 2020

Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib

1 reference

12 December 2020

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

12 December 2020

Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).

1 reference

12 December 2020

Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.

1 reference

12 December 2020

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

1 reference

12 December 2020

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

12 December 2020

Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae.

1 reference

12 December 2020

Integration of EGFR inhibitors with radiochemotherapy

1 reference

12 December 2020

Erlotinib in previously treated non-small-cell lung cancer

1 reference

12 December 2020

Ultraviolet irradiation induces keratinocyte proliferation and epidermal hyperplasia through the activation of the epidermal growth factor receptor

1 reference

12 December 2020

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

1 reference

12 December 2020

Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1.

1 reference

12 December 2020

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib

1 reference

12 December 2020

Pharmacogenetics of ABCG2 and adverse reactions to gefitinib

1 reference

12 December 2020

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

1 reference

12 December 2020

Gefitinib has the potential of activating cell immunity against malignant cells

1 reference

12 December 2020

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

12 December 2020

Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects

1 reference

12 December 2020

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

12 December 2020

Temporal dependence of the effect of radiation on erlotinib-induced skin rash

1 reference

12 December 2020

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

1 reference

12 December 2020

Issues and progress with protein kinase inhibitors for cancer treatment

1 reference

12 December 2020

Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer

1 reference

12 December 2020

Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity

1 reference

12 December 2020